Skip to main content

Merck & Company (MRK-N) Quote

Register
AdChoices
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 88.91
Day High 89.96
Open:89.04
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Latest
inside the market
Market movers: Stocks that saw action on Monday - and why
Subscriber content
u.s. business
Merck wins European approval for first-ever Ebola vaccine
Subscriber content
top links
3 actionable stock ideas in 30 seconds
Subscriber content
inside the market
What every Canadian investor needs to know today
Subscriber content
report on business
Merck Canada says new drug price regulations are unconstitutional
international business
Elanco to become No. 2 in animal health with $7.6-billion Bayer deal
Subscriber content
Description
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

View Earnings zacks

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

View Estimates zacks

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Download Report (PDF) Thomson Reuters

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Download Report (PDF) StockCalc

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Download Report (PDF) ValueEnfine

Latest Press Releases

More Stories
BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium(R)
- GlobeNewswire - Fri Dec 13, 5:30AM CST
GlobeNewswire - CMTX
Fri Dec 13, 5:30AM CST
Safety and early efficacy data were presented on December 12 at 6:00 p.m. ET from the clinical trials of Bria-IMT(TM) in combination with immune checkpoint inhibitors in advanced breast cancer:
SHAREHOLDER ALERT: WeissLaw LLP Investigates ArQule, Inc.
- PR Newswire - Thu Dec 12, 2:49PM CST
PR Newswire - CMTX
Thu Dec 12, 2:49PM CST
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of ArQule, Inc. ("ArQule" or the "Company") (NASDAQ: ARQL) in connection with the proposed acquisition of the Company by a subsidiary of Merck & Co., Inc. (NYSE: MRK). Under the terms of the acquisition agreement, ARQL shareholders will receive $20 per share in cash. The deal is scheduled to close in the first quarter of 2020.
SHAREHOLDER ALERT: WeissLaw LLP Investigates ArQule, Inc.
- PR Newswire - Thu Dec 12, 2:49PM CST
PR Newswire - PRNW
Thu Dec 12, 2:49PM CST
NEW YORK , Dec. 12, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of ArQule, Inc. ("ArQule" or the "Company") (NASDAQ: ARQL) in connection with the proposed acquisition of the Company by a subsidiary of Merck & Co., Inc. (NYSE: MRK). Under the terms of the acquisition agreement, ARQL shareholders will receive $20 per share in cash. The deal is scheduled to close in the first quarter of 2020.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 83.70 +7.01% increase
on 11/14/19
Period Open:84.12
Price movement based on the high, low and last over the given period.
89.96 -0.43% decrease
on 12/12/19
 +5.45 (+6.48%) increase
since 11/12/19
3-Month 80.25 +11.61% increase
on 10/22/19
Period Open:83.31
Price movement based on the high, low and last over the given period.
89.96 -0.43% decrease
on 12/12/19
 +6.26 (+7.51%) increase
since 09/12/19
52-Week 70.89 +26.35% increase
on 12/24/18
Period Open:78.01
Price movement based on the high, low and last over the given period.
89.96 -0.43% decrease
on 12/12/19
 +11.56 (+14.82%) increase
since 12/12/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies